title: Impairment of lymphocyte function following yttrium-90 DOTATOC therapy.
abstract: The radiolabeled somatostatin analogue, yttrium-90 DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC), is currently applied to treat advanced somatostatin receptor-positive tumors, e.g., neuroendocrine tumors of the pancreas, lung or gut. However, effects of this treatment on antimicrobial immune responses are not yet defined. In 20 patients treated with DOTATOC, cellular in vitro immune function was determined. Their antimicrobial lymphocyte responses were assessed by lymphocyte transformation test and enzyme-linked immunospot-measuring lymphocyte proliferation and on a single cell level production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10)-prior to therapy, at day 1, day 7 and day 90 post-therapy. Proliferative lymphocyte responses and interferon-γ production after in vitro stimulation with microbial antigens were non-significantly suppressed at day 1 and significantly (p < 0.05) at day 7 versus pre-therapy. In vitro immune responses did not fully recover until day 90. In contrast, at day 1 interleukin-10 production was significantly (p < 0.05) increased. Taken together, we observed a decrease in pro-inflammatory immune responses after DOTATOC therapy. Patients with versus without bone metastases displayed significantly (p < 0.05) lower cellular immune responses toward several microbial antigens. Progressive disease and higher tumor burden could also be defined as factors associated with impaired immune function. Spearman correlation analysis indicated that cellular in vitro immunity was positively correlated with kidney function; better kidney function led to stronger immune responses. In conclusion, DOTATOC therapy caused a decrease in in vitro immune responses against microorganisms. The clinical impact needs to be evaluated in further studies.
authors.affiliation: Institute of Nuclear Medicine, Helios Kliniken, Schwerin, Germany.
authors.forename: Vahé
authors.initials: V
authors.lastname: Barsegian
authors.forename: Christian
authors.initials: C
authors.lastname: Hueben
authors.forename: Stefan P
authors.initials: SP
authors.lastname: Mueller
authors.forename: Thorsten D
authors.initials: TD
authors.lastname: Poeppel
authors.forename: Peter A
authors.initials: PA
authors.lastname: Horn
authors.forename: Andreas
authors.initials: A
authors.lastname: Bockisch
authors.forename: Monika
authors.initials: M
authors.lastname: Lindemann
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000276:immunology / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000209:etiology / Q000276:immunology*; D017481:Receptors, Somatostatin / Q000096:biosynthesis; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide
references.citation: Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1179-84
references.pmid: 21601995
references.citation: J Nucl Med. 2001 Nov;42(11):1697-703
references.pmid: 11696642
references.citation: Cancer Biother Radiopharm. 2002 Feb;17(1):119-28
references.pmid: 11915169
references.citation: Radiat Res. 1988 Nov;116(2):254-62
references.pmid: 3055011
references.citation: Exp Cell Biol. 1980;48(4):255-78
references.pmid: 6967433
references.citation: Ann ICRP. 1998;28(3):1-126
references.pmid: 10840563
references.citation: J Transl Med. 2013 Jan 15;11:17
references.pmid: 23320604
references.citation: Radiat Environ Biophys. 1982;20(4):275-87
references.pmid: 7146319
references.citation: Phys Med Biol. 1996 Oct;41(10):1871-84
references.pmid: 8912367
references.citation: Cancer Immunol Immunother. 2004 Nov;53(11):1051
references.pmid: 15232653
references.citation: Int J Rad Appl Instrum B. 1991;18(5):469-76
references.pmid: 1917516
references.citation: Radiat Res. 2003 Jun;159(6):812-34
references.pmid: 12751965
references.citation: J Nucl Med. 1985 Nov;26(11):1243-7
references.pmid: 3903074
references.citation: AIDS. 2004 Oct 21;18(15):2001-7
references.pmid: 15577621
references.citation: Exp Hematol. 2004 Nov;32(11):1103-9
references.pmid: 15539089
references.citation: Scand J Immunol. 1976;5(4):323-9
references.pmid: 781796
references.citation: Ann ICRP. 1987;18(1-4):1-377
references.pmid: 3505163
references.citation: J Nucl Med. 2006 Apr;47(4):648-54
references.pmid: 16595499
references.citation: Clin Cancer Res. 1996 Mar;2(3):457-70
references.pmid: 9816191
references.citation: Radiother Oncol. 1999 Feb;50(2):199-204
references.pmid: 10368044
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6115-20
references.pmid: 18420820
references.citation: Nuklearmedizin. 2011;50(5):195-203
references.pmid: 21887454
references.citation: Lancet. 1998 Feb 7;351(9100):417-8
references.pmid: 9482300
references.citation: Adv Immunol. 1976;24:215-335
references.pmid: 14486
references.citation: Cancer Res. 1989 May 15;49(10):2639-44
references.pmid: 2785435
references.citation: Semin Nucl Med. 2006 Jul;36(3):228-47
references.pmid: 16762613
references.citation: Eur J Nucl Med. 2001 Dec;28(12):1743-50
references.pmid: 11734910